Pfizer 1Q Revenues: $12.8 billion (-2%) 1Q Earnings: $3.1 billion (+3%) Comments: Innovative Health sales were $7.4 billion in the quarter, up 5% driven by key brands including Ibrance and Eliquis, the addition of Xtandi revenues in the U.S. resulting from the September 2016 acquisition of Medivation, as well as Lyrica and Xeljanz, both primarily in the U.S., offset by lower revenues for Enbrel due to continued biosimilar competition, as well as Viagra in the U.S., primarily due to lowe...